UK Set To Launch Drug Repurposing Project
Plans Include Extended Protection Periods And New ‘Catalyst Fund’
Executive Summary
Licensing new uses of existing medicines has several benefits over off-label use, such as offering assurances that the indication is evidence based and subject to an ongoing safety monitoring program, according to a new report.
You may also be interested in...
EU Drug Repurposing Pilot Kicks Off
A new European initiative will offer scientific advice, fee waivers and other support to not-for-profit and academic sponsors to help them find new uses for existing medicines and hook up with commercial companies to seek marketing authorization.
UK Weathers Challenges Of COVID-19 And Brexit
Departing BGMA leader Warwick Smith highlights successes in the UK off-patent industry’s response to the COVID-19 pandemic but offers unambiguous criticism of Brexit in the concluding part of an exclusive interview with Generics Bulletin.
EU Drug Repurposing Project To Kick Off In Q1 2020
Finding new uses for older drugs is the objective of a European repurposing project that will begin in early 2020.